Tundra Space

Tundra Space

Clinical Research Directory

Browse clinical research sites, groups, and studies.

Back to Studies
COMPLETED
NCT04483973
PHASE2

SPI-1005 Treatment in Severe COVID-19 Patients

Sponsor: Sound Pharmaceuticals, Incorporated

View on ClinicalTrials.gov

Summary

The study is a randomized, double-blind, placebo-controlled, dose escalation, multi-center clinical trial (RCT) of SPI-1005 in adult subjects with positive PCR test for novel SARS-CoV-2 (nCoV2) and severe symptoms of COVID-19 disease.

Official title: A Phase 2, Randomized, Double-Blind, Placebo-Controlled, Dose Escalation Study to Evaluate the Safety and Efficacy of SPI-1005 in Severe COVID-19 Patients

Key Details

Gender

All

Age Range

18 Years - Any

Study Type

INTERVENTIONAL

Enrollment

25

Start Date

2021-08-27

Completion Date

2023-06-06

Last Updated

2026-06-29

Healthy Volunteers

No

Interventions

DRUG

Ebselen

Glutathione peroxidase mimetic

DRUG

Placebo

Matching placebo containing excipients

Locations (7)

Yale University

New Haven, Connecticut, United States

St. Luke's Cystic Fibrosis Center of Idaho

Boise, Idaho, United States

Kansas University Medical Center

Kansas City, Kansas, United States

Washington University in St. Louis

St Louis, Missouri, United States

Duke University

Durham, North Carolina, United States

Wake Forest University

Winston-Salem, North Carolina, United States

University of Texas Southwestern

Dallas, Texas, United States